Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ART022
MIFTS: 68

Arthritis

Categories: Bone diseases, Genetic diseases, Immune diseases, Liver diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Arthritis

About this section

MalaCards integrated aliases for Arthritis:

Name: Arthritis 11 75 28 53 5 41 2 43 14 36 16 71
Inflammatory Joint Disease 53 71
Inflammatory Disorder of Joint 11

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Bone diseases Immune diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:848
MeSH 43 D001168
NCIt 49 C2883
SNOMED-CT 68 372091005
ICD10 31 M13.8 M13.9
UMLS 71 C0003864 C0683381
Sources

Summaries for Arthritis

About this section

MedlinePlus: 41 If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include: Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary: Arthritis, also known as inflammatory joint disease, is related to rheumatoid arthritis and psoriatic arthritis, and has symptoms including joint stiffness, back pain and arthralgia. An important gene associated with Arthritis is SYK (Spleen Associated Tyrosine Kinase), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Leflunomide and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include joint, bone and bone marrow, and related phenotypes are Decreased Tat-dependent HIV-LTR-beta-galactosidase protein expression and homeostasis/metabolism

CDC: 2 Arthritis means inflammation or swelling of one or more joints. It describes more than 100 conditions that affect the joints, tissues around the joint, and other connective tissues. Specific symptoms vary depending on the type of arthritis, but usually include joint pain and stiffness.

Disease Ontology: 11 A bone inflammation disease that involves a response to irritation or injury, characterized by joint pain, swelling, stiffness located in joint.

Wikipedia: 75 Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include... more...
Sources

Related Diseases for Arthritis

About this section

Diseases in the Arthritis family:

Juvenile Arthritis Transient Arthritis

Diseases related to Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2983)
# Related Disease Score Top Affiliating Genes
1 rheumatoid arthritis 34.4 TNFAIP6 TNF SYK STAT4 PTPN22 PADI4
2 psoriatic arthritis 34.2 TNF PTPN22 MMP9 MMP3 LTA IL6
3 juvenile rheumatoid arthritis 34.1 TNF PTPN22 LTA IL6 IL1A HLA-DRB1
4 septic arthritis 33.9 TNF MMP3 MMP13 IL6 IL17A CXCL8
5 spondyloarthropathy 1 33.7 TNF MMP3 IL6 IL17A
6 osteoarthritis 33.6 TNFAIP6 TNF MMP9 MMP3 MMP13 IL6
7 systemic onset juvenile idiopathic arthritis 33.5 MIF IL6 HLA-DRB1
8 juvenile arthritis 33.4 MIF IL6
9 autoimmune disease 33.3 TNF STAT4 PTPN22 PADI4 MMP9 MIF
10 psoriasis 33.2 TNF PTPN22 LTA IL6 IL1A IL17A
11 systemic lupus erythematosus 33.1 TNF SYK STAT4 PTPN22 PADI4 MMP9
12 temporal arteritis 33.1 TNF PTPN22 MMP3 IL6 IL17A HLA-DRB1
13 rheumatoid arthritis, systemic juvenile 33.1 MIF IL6
14 oligoarticular juvenile idiopathic arthritis 33.0 STAT4 PTPN22
15 lyme disease 33.0 TNF MMP9 IL6 IL17A HLA-DRB1
16 behcet syndrome 32.9 TNF STAT4 PTPN22 LTA IL6 IL1A
17 arthropathy 32.9 TNF MMP3 MMP13 LTA IL6
18 cartilage disease 32.9 TNF MMP3 MMP13 IL6
19 rheumatoid factor-negative polyarticular juvenile idiopathic arthritis 32.8 STAT4 PTPN22
20 systemic scleroderma 32.8 TNF STAT4 IL6 IL17A HLA-DRB1 CXCL8
21 osteoporosis 32.8 TNF MMP9 MMP3 LTA IL6 IL1A
22 connective tissue disease 32.8 TNF MMP9 MMP3 MMP13 IL6 IL1A
23 transient arthritis 32.8 TNF IL6 IL17A
24 spondylitis 32.8 TNF LTA IL6 IL17A HLA-DRB1
25 rheumatoid arthritis interstitial lung disease 32.7 TNF HLA-DRB1
26 interstitial lung disease 32.7 TNF MMP9 IL6 IL1A CXCL8
27 mixed connective tissue disease 32.6 TNF IL6 IL1A HLA-DRB1
28 adult-onset still's disease 32.6 TNF IL6 IL1A
29 brucellosis 32.6 TNF IL6 IL17A CXCL8
30 synovitis 32.6 TNF RELN MMP9 MMP3 MMP13 IL6
31 sarcoidosis 1 32.6 TNF MIF LTA IL6 IL1A IL17A
32 fibromyalgia 32.6 TNF IL6 CXCL8
33 uveitis 32.6 TNF LTA IL6 IL1A IL17A HLA-DRB1
34 back pain 32.5 MMP3 IL6 CXCL8
35 dermatitis 32.5 TNF IL6 IL1A IL17A CXCL8
36 crohn's disease 32.5 TNF IL6 IL17A CXCL8
37 vitiligo-associated multiple autoimmune disease susceptibility 1 32.5 TNF PTPN22 IL17A
38 acne 32.4 TNF IL6 IL1A IL17A CXCL8
39 lung disease 32.4 TNF MMP9 LTA IL6 IL1A CXCL8
40 chikungunya 32.4 TNF IL6 IL17A
41 bronchiolitis obliterans 32.4 TNF MMP9 IL6 IL17A CXCL8
42 vasculitis 32.4 TNF IL6 IL17A HLA-DRB1 CXCL8
43 bone disease 32.4 TNF MMP9 MMP13 LTA IL6
44 dermatitis, atopic 32.4 TNF SYK MIF LTA IL6 IL1A
45 tenosynovitis 32.4 TNF MMP3 IL6 IL17A
46 osteomyelitis 32.3 TNF IL6 IL1A CXCL8
47 scleritis 32.3 TNF PTPN22 MMP9
48 pemphigus 32.3 TNF IL6 IL17A HLA-DRB1
49 periodontitis 32.3 TNF MMP9 MMP3 MMP13 IL6 IL1A
50 exanthem 32.3 TNF IL6 IL17A CXCL8

Graphical network of the top 20 diseases related to Arthritis:



Diseases related to Arthritis
Sources

Symptoms & Phenotypes for Arthritis

About this section

UMLS symptoms related to Arthritis:


joint stiffness; back pain; arthralgia; sciatica; muscle cramp; metatarsalgia

GenomeRNAi Phenotypes related to Arthritis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased Tat-dependent HIV-LTR-beta-galactosidase protein expression GR00224-A-2 8.8 IL1A MMP13 MMP9

MGI Mouse Phenotypes related to Arthritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 CPT2 IL17A IL1A IL6 LTA MACIR
2 immune system MP:0005387 10.13 CPT2 IL17A IL1A IL6 LTA MIF
3 cardiovascular system MP:0005385 10.06 CPT2 IL1A IL6 LTA MIF MMP13
4 respiratory system MP:0005388 9.81 CPT2 IL17A IL6 LTA MMP9 PTPN22
5 skeleton MP:0005390 9.65 CPT2 HLA-DRB1 IL17A IL6 LTA MMP13
6 hematopoietic system MP:0005397 9.44 IL17A IL1A IL6 LTA MIF MMP3
Sources

Drugs & Therapeutics for Arthritis

About this section

Drugs for Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 765)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Sulfasalazine Approved Phase 4 599-79-1 5353980 5339 5359476
4
Chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
5
Calcium carbonate Approved, Investigational Phase 4 471-34-1
6
Atorvastatin Approved Phase 4 134523-00-5 60823
7
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
8
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
9
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
10
Aminocaproic acid Approved, Investigational Phase 4 60-32-2 564
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
12
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
13
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
14
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
15
Ibuprofen Approved Phase 4 15687-27-1 3672
16
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
17
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
18
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
19
Roxithromycin Approved, Investigational, Withdrawn Phase 4 80214-83-1 6915744
20
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
21
Denosumab Approved Phase 4 615258-40-7
22
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
23
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
24
Valdecoxib Approved, Investigational, Withdrawn Phase 4 181695-72-7 119607
25
Aceclofenac Approved, Investigational Phase 4 89796-99-6 71771
26
Pheniramine Approved Phase 4 86-21-5 4761
27
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
28
Promethazine Approved, Investigational Phase 4 60-87-7 4927
29
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
30
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
31
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
32
Minocycline Approved, Investigational Phase 4 10118-90-8, 13614-98-7 54675783 5281021
33
Famotidine Approved Phase 4 76824-35-6 3325 5702160
34
Milnacipran Approved, Investigational Phase 4 92623-85-3, 96847-54-0 11622909 65833 6917779
35
Ibandronate Approved, Investigational Phase 4 114084-78-5 60852
36
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850 155817470
37
Ticagrelor Approved Phase 4 274693-27-5 9871419
38
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
39
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
40
Bazedoxifene Approved, Investigational Phase 4 198481-32-2 154257
41
Mepivacaine Approved, Vet_approved Phase 4 96-88-8, 1722-62-9 4062
42
Prilocaine Approved Phase 4 721-50-6 4906
43
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
44
Vecuronium Approved, Investigational Phase 4 50700-72-6, 86029-43-8 39765 39764
45
Desflurane Approved Phase 4 57041-67-5 42113
46
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
47
Remifentanil Approved Phase 4 132875-61-7 60815
48
Reviparin Approved, Investigational Phase 4 9041-08-1
49
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
50
Ixekizumab Approved, Investigational Phase 4 1143503-69-8

Interventional clinical trials:

(show top 50) (show all 4294)
# Name Status NCT ID Phase Drugs
1 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
2 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis - a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
3 Prevalence, Pattern and Disease Course og Arthritis and Enthesitis in Patients With Psoriasis, and Effect of Apremilast in Subclinical, US-defined Psoriatic Arthritis - a Population Based Study Applying Clinical, Ultrasonic, MRI and Patient-reported Outcomes Unknown status NCT04515732 Phase 4 Apremilast Oral Tablet
4 Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4 Adalimumab;Methotrexate
5 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
6 Prospective Randomized Multicentric Trial on Anti-TNFα Treatment and Infection Risk in the Perioperative Period During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis. Unknown status NCT02242474 Phase 4 Anti-TNF suspended perioperatively;Anti-TNFα continued perioperatively
7 Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis Unknown status NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
8 The Bucillamine Study of Holding Remission After Infliximab Dose-off in Patients With Rheumatoid Arthritis Receiving Methotrexate Unknown status NCT00716248 Phase 4 bucillamine;methotrexate
9 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
10 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy Unknown status NCT02087696 Phase 4 Tocilizumab
11 Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA) Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
12 Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial Unknown status NCT01907230 Phase 4 Entecavir
13 Concentration-guided Dose Reduction Versus Standard Dosing in Tocilizumab-treated Rheumatoid Arthritis Patients: a Randomised, Multicenter, Non-inferiority Trial (TODORA) Unknown status NCT03895879 Phase 4 Tocilizumab
14 Serum Calprotectin Level in Patients With Rheumatoid Arthritis and Osteoarthritis Unknown status NCT04201886 Phase 4
15 Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB Unknown status NCT04106804 Phase 4 Abatacept 125 MG/ML
16 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
17 Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA): Multi-centre Open Label Randomised Controlled Trail Unknown status NCT04194827 Phase 4 Adalimumab
18 Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
19 A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
20 Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects With Rheumatoid Arthritis Unknown status NCT03882008 Phase 4 Abatacept
21 Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity: a Single Blind, Non-inferiority, Randomised Clinical Trial Unknown status NCT04222920 Phase 4 Adalimumab
22 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Unknown status NCT02275299 Phase 4 Iguratimod;Leflunomide;Methotrexate
23 Bone Resorption, Osteoclastogenesis and Adalimumab Unknown status NCT02035800 Phase 4 Adalimumab
24 Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs Unknown status NCT03082573 Phase 4 H.P. Acthar gel
25 Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
26 The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis Unknown status NCT01980836 Phase 4
27 Effect of Sarilumab Therapy on Atherosclerotic Disease Assessed by Positron Emission Tomography/Computed Tomography (PET/CT) in Patients With Rheumatoid Arthritis Unknown status NCT04350216 Phase 4 Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
28 Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis Unknown status NCT03781310 Phase 4 Tocilizumab
29 Interventional Study on the Effectiveness and Safety of Intensive Exercise in Patients With RA Unknown status NCT00434200 Phase 4
30 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
31 The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee Unknown status NCT03215407 Phase 4 Intra-articular Tocilizumab;Intra-articular Compound Betamethasone
32 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
33 Use of TNF-blocking Therapy in Combination With DMARDs in Patients With Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
34 Safety and Efficacy of Optimal Methotrexate With Folic Acid in Patients With Rheumatoid Arthritis in Meizhou, Guangdong: a Randomized Case-control Study Unknown status NCT04066803 Phase 4 MTX;Folic Acid;DMARDs
35 Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks Unknown status NCT00216177 Phase 4 Infliximab;Adalimumab
36 Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial Unknown status NCT03227419 Phase 4 Tocilizumab Prefilled Syringe;Abatacept Prefilled Syringe
37 Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis Unknown status NCT04464642 Phase 4 Methotrexate;Tofacitinib
38 Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis (STARA) Clinical Trial Unknown status NCT01793519 Phase 4 Etanercept;Infliximab;Adalimumab;Placebo
39 The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work Unknown status NCT01405326 Phase 4
40 Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status NCT01752335 Phase 4
41 When and in Whom to Stop Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept
42 A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod Alone or Iguratimod in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis Unknown status NCT01548001 Phase 4 Iguratimod;Methotrexate
43 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
44 Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis Unknown status NCT01282528 Phase 4
45 Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From "Real World" and Investigating Its Mechanism Through Signal Pathway Unknown status NCT02878161 Phase 4 methotrexate(necessary);leflunomide (permitted, not necessary);NSAIDs (permitted,not necessary);Glucocorticoids (permitted,not necessary)
46 Improving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection Against A Preventable Cause Of Death In An At Risk Population? Unknown status NCT02936180 Phase 4
47 Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate Unknown status NCT01270035 Phase 4 Adalimumab
48 Prospective Clinical Study to Observe the Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment in China Unknown status NCT02837978 Phase 4 Tacrolimus;MTX
49 Canadian Orthopaedic Foot and Ankle Society Surgical Treatment of Ankle Arthritis Outcome Study Unknown status NCT00552136 Phase 4
50 Towards Efficient Prediction and Prevention of Rheumatoid Arthritis Unknown status NCT04115397 Phase 4 Zoledronic Acid;Placebo

Search NIH Clinical Center for Arthritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Devil's claw preparation
Meclofenamate
Meclofenamate Sodium
Salsalate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Arthritis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Arthritis:
AlloStem, adipose-derived mesenchymal stem cells combined with allograft bone for bone grafting
Embryonic/Adult Cultured Cells Related to Arthritis:
Adipose-derived mesenchymal stem cells combined with allograft bone (AlloStem) PMIDs: 22500696

Cochrane evidence based reviews: arthritis

Sources

Genetic Tests for Arthritis

About this section

Genetic tests related to Arthritis:

# Genetic test Affiliating Genes
1 Arthritis 28
Sources

Anatomical Context for Arthritis

About this section

Organs/tissues related to Arthritis:

FMA: Joint
MalaCards : Bone, Bone Marrow, Skin, T Cells, B Cells, Lung, Endothelial
Sources

Publications for Arthritis

About this section

Articles related to Arthritis:

(show top 50) (show all 31863)
# Title Authors PMID Year
1
Two phenotypes of chronic recurrent multifocal osteomyelitis with different patterns of bone involvement. 41
36456962 2022
2
Prevalence of multimorbidity combinations and their association with medical costs and poor health: A population-based study of U.S. adults. 41
36466476 2022
3
Changes in coverage among non-elderly adults with chronic diseases following Affordable Care Act implementation. 41
36449511 2022
4
Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. 53 62
20436077 2010
5
Curcumin attenuates inflammatory response in IL-1beta-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. 53 62
20188213 2010
6
The axis of thrombospondin-1, transforming growth factor beta and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis. 53 62
19485899 2010
7
Pregnancy during TNFalpha antagonist therapy: beware the rifampin-oral contraceptive interaction. Report of two cases. 53 62
20447852 2010
8
Th17 cytokines and arthritis. 53 62
20127485 2010
9
Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. 53 62
20008919 2010
10
Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever. 53 62
19533138 2010
11
Mammalian clock gene Cryptochrome regulates arthritis via proinflammatory cytokine TNF-alpha. 53 62
20042581 2010
12
IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis? 53 62
20192994 2010
13
Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. 53 62
19866480 2010
14
Red ginseng saponin extract attenuates murine collagen-induced arthritis by reducing pro-inflammatory responses and matrix metalloproteinase-3 expression. 53 62
20410593 2010
15
Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. 53 62
19176545 2010
16
Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model. 53 62
19655230 2010
17
Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. 53 62
19949094 2010
18
c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. 53 62
20181277 2010
19
IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. 53 62
19895848 2010
20
Interleukin-6 subfamily cytokines and rheumatoid arthritis: role of antagonists. 53 62
19804846 2010
21
Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. 53 62
20067641 2010
22
PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. 53 62
19734303 2009
23
Gadd45beta deficiency in rheumatoid arthritis: enhanced synovitis through JNK signaling. 53 62
19877043 2009
24
IL-17 as a future therapeutic target for rheumatoid arthritis. 53 62
19798029 2009
25
Identification of NR4A2 as a transcriptional activator of IL-8 expression in human inflammatory arthritis. 53 62
19732956 2009
26
CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis. 53 62
19790057 2009
27
Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF. 53 62
19717512 2009
28
Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. 53 62
19644886 2009
29
Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. 53 62
18678578 2009
30
Effects of triptolide from Radix Tripterygium wilfordii (Leigongteng) on cartilage cytokines and transcription factor NF-kappaB: a study on induced arthritis in rats. 53 62
19570240 2009
31
NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain. 53 62
19479837 2009
32
Synovial fluid RANKL and matrix metalloproteinase levels in enthesitis related arthritis subtype of juvenile idiopathic arthritis. 53 62
19052752 2009
33
Anakinra for systemic juvenile arthritis: the Rocky Mountain experience. 53 62
19363453 2009
34
Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. 53 62
19358841 2009
35
Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model. 53 62
18495731 2009
36
Oncostatin M-induced CCL2 transcription in osteoblastic cells is mediated by multiple levels of STAT-1 and STAT-3 signaling: an implication for the pathogenesis of arthritis. 53 62
19404962 2009
37
A novel matrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects. 53 62
18985071 2009
38
Pathogenesis of rheumatoid arthritis and c-Fos/AP-1. 53 62
19395871 2009
39
Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. 53 62
19333931 2009
40
CCAAT/enhancer binding protein beta mediates expression of matrix metalloproteinase 13 in human articular chondrocytes in inflammatory arthritis. 53 62
19248099 2009
41
Proteinase activated receptor (PAR) involvement in mediating arthritis pain and inflammation. 53 62
19184346 2009
42
The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. 53 62
19248102 2009
43
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. 53 62
19248109 2009
44
Cartilage Oligomeric Matrix Protein (COMP): A Biomarker of Arthritis. 53 62
19652761 2009
45
Lessons from animal models of arthritis over the past decade. 53 62
19849822 2009
46
The effect of triptolide on CD4+ and CD8+ cells in the Peyer's patch of DA rats with collagen induced arthritis. 53 62
19921588 2009
47
IL-10 is critically involved in mycobacterial HSP70 induced suppression of proteoglycan-induced arthritis. 53 62
19142233 2009
48
Tumor necrosis factor alpha-induced adipose-related protein expression in experimental arthritis and in rheumatoid arthritis. 53 62
19660107 2009
49
Follistatin-like protein 1 promotes arthritis by up-regulating IFN-gamma. 53 62
19109154 2009
50
The role of ADAMTS-7 and ADAMTS-12 in the pathogenesis of arthritis. 53 62
19098927 2009
Sources

Variations for Arthritis

About this section

ClinVar genetic disease variations for Arthritis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SYK NM_003177.7(SYK):c.1649C>A (p.Ser550Tyr) SNV Pathogenic
 989389 rs1828636794 GRCh37: 9:93650098-93650098
GRCh38: 9:90887816-90887816
2 RELN NM_005045.4(RELN):c.7456A>G (p.Ser2486Gly) SNV Pathogenic
 684430 rs760019076 GRCh37: 7:103163872-103163872
GRCh38: 7:103523425-103523425
3 CPT2 NM_000098.3(CPT2):c.149C>A (p.Pro50His) SNV Pathogenic
 8954 rs28936375 GRCh37: 1:53662764-53662764
GRCh38: 1:53197092-53197092
4 SYK NM_003177.7(SYK):c.1024C>A (p.Pro342Thr) SNV Likely Pathogenic
 989387 rs1827861920 GRCh37: 9:93636974-93636974
GRCh38: 9:90874692-90874692
5 SYK NM_003177.7(SYK):c.1350G>A (p.Met450Ile) SNV Likely Pathogenic
 989237 rs1304839707 GRCh37: 9:93640021-93640021
GRCh38: 9:90877739-90877739
6 SYK NM_003177.7(SYK):c.1057G>A (p.Ala353Thr) SNV Uncertain Significance
 989236 rs200167353 GRCh37: 9:93637007-93637007
GRCh38: 9:90874725-90874725
Sources

Expression for Arthritis

About this section
Search GEO for disease gene expression data for Arthritis.
Sources

Pathways for Arthritis

About this section

Pathways related to Arthritis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.83 TNFAIP6 TNF SYK STAT4 PTPN22 MMP9
2
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.63 TNFAIP6 TNF MMP9 MMP3 MIF LTA
3
Akt Signaling 64
Show member pathways
 13.42 TNFAIP6 TNF SYK STAT4 LTA IL6
4
PAK Pathway 64
Show member pathways
 13.31 CXCL8 IL17A IL1A IL6 LTA PTPN22
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.18 CXCL8 HLA-DRB1 IL17A IL1A IL6 LTA
6
Toll-like receptor signaling pathway 74
Show member pathways
 12.83 CXCL8 IL1A IL6 MMP9 STAT4 SYK
7
IL-1 Family Signaling Pathways 65
Show member pathways
 12.63 TNF SYK IL6 IL1A CXCL8
8
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.63 TNF STAT4 LTA IL6 IL1A IL17A
9
NF-kappaB Signaling 3
12.58 IL17A PTPN22 STAT4 SYK TNF
10
Bacterial infections in CF airways 22
Show member pathways
 12.41 TNF IL6 IL1A CXCL8
11
Toll Comparative Pathway 64
Show member pathways
 12.34 TNF MIF IL6 IL1A CXCL8
12
IL-17 Family Signaling Pathways 65
Show member pathways
 12.2 TNF MMP9 MMP3 MMP13 IL6 IL17A
13
Sudden infant death syndrome (SIDS) susceptibility pathways 74
12.19 TNF IL6 IL1A CXCL8
14
T-cell activation SARS-CoV-2 74
Show member pathways
 12.15 TNF STAT4 LTA IL17A HLA-DRB1
15
Neuroinflammation and glutamatergic signaling 74
12.12 TNF LTA IL6 IL1A
16
Matrix metalloproteinases 74
Show member pathways
 11.94 TNF MMP9 MMP3 MMP13
17
Spinal cord injury 74
11.94 TNF MMP9 MIF IL6 IL1A CXCL8
18
IL27-mediated signaling events 61
Show member pathways
 11.93 TNF STAT4 LTA IL6 IL17A
19
CCL18 signaling pathway 74
11.88 MMP3 IL6 CXCL8
20
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.86 IL6 IL17A CXCL8
21
Allograft rejection 74
11.86 TNF IL1A IL17A HLA-DRB1 CXCL8
22
Th17 Differentiation 65
Show member pathways
 11.85 STAT4 IL6 IL17A
23
Angiogenesis (CST) 3
11.84 MMP9 MMP3 MMP13
24
Burn wound healing 74
11.8 TNF MMP9 IL6 CXCL8
25
Innate Lymphoid Cells Differentiation 65
11.79 TNF LTA IL17A
26
Network map of SARS-CoV-2 signaling pathway 74
Show member pathways
 11.77 IL6 HLA-DRB1 CXCL8
27
Extrafollicular B cell activation by SARS-CoV-2 74
11.73 TNF SYK IL6
28
Interleukin-4 and Interleukin-13 signaling 66
11.73 TNF MMP9 MMP3 IL6 IL1A IL17A
29
AP-1 transcription factor network 61
11.71 MMP9 IL6 CXCL8
30
Lung fibrosis 74
11.71 CXCL8 IL6 MMP9 TNF
31
miRNAs involvement in the immune response in sepsis 74
11.7 TNF IL6 IL1A CXCL8
32
IL 10 signaling pathway 67
11.69 TNF LTA IL6 IL1A
33
Cell adhesion_ECM remodeling 22
11.68 MMP9 MMP3 MMP13 CXCL8
34
Inflammatory bowel disease signaling 74
Show member pathways
 11.65 TNF STAT4 IL6 IL1A
35
Transcription_NF-kB signaling pathway 22
11.6 IL1A LTA TNF
36
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.58 TNF IL6 CXCL8
37
Nonalcoholic fatty liver disease 74
11.53 TNF IL6 IL1A
38
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.52 TNF IL6 IL1A
39
Interleukin-10 signaling 66
11.52 TNF IL6 IL1A CXCL8
40
Fibrin complement receptor 3 signaling pathway 74
11.49 TNF SYK IL6
41
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling 61
11.44 MMP9 MMP3 MMP13
42
Validated transcriptional targets of AP1 family members Fra1 and Fra2 61
11.39 MMP9 IL6 CXCL8
43
IL-10 Pathway 64
11.38 TNF IL6 IL1A
44
Development and heterogeneity of the ILC family 74
11.34 TNF IL6 IL17A
45
amb2 Integrin signaling 61
11.29 TNF MMP9 IL6
46
Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway 74
11.29 TNF MMP3 IL6 CXCL8
47
Cytokines and inflammatory response 74
11.24 TNF IL6 IL1A HLA-DRB1
48
Immune infiltration in pancreatic cancer 74
11.19 CXCL8 IL17A IL6 TNF
49
Overview of nanoparticle effects 74
11.09 TNF IL6 CXCL8
50
G-protein signaling_Rap2B regulation pathway 22
11.03 TNF LTA IL6 IL1A IL17A CXCL8
Sources

GO Terms for Arthritis

About this section

Cellular components related to Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 TNFAIP6 TNF RELN MMP9 MMP3 MMP13
2 extracellular space GO:0005615 9.74 CXCL8 HLA-DRB1 IL17A IL1A IL6 LTA

Biological processes related to Arthritis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.25 HLA-DRB1 IL1A MIF PTPN22 TNF
2 positive regulation of protein phosphorylation GO:0001934 10.19 TNF RELN MMP9 MIF HLA-DRB1
3 defense response to Gram-positive bacterium GO:0050830 10.16 TNF LTA IL6 IL17A
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.13 IL6 MIF RELN SYK
5 positive regulation of MAPK cascade GO:0043410 10.11 FCRL3 HLA-DRB1 IL6 SYK TNF
6 immune response GO:0006955 10.1 TNF LTA IL6 IL1A IL17A HLA-DRB1
7 extracellular matrix disassembly GO:0022617 10.07 MMP9 MMP3 MMP13
8 collagen catabolic process GO:0030574 10.05 MMP9 MMP3 MMP13
9 immune system process GO:0002376 10.04 SYK PTPN22 PADI4 MIF IL17A HLA-DRB1
10 positive regulation of cytokine production GO:0001819 10.02 TNF SYK MIF IL1A
11 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.99 TNF IL6 IL17A
12 humoral immune response GO:0006959 9.97 TNF LTA IL6 HLA-DRB1
13 positive regulation of glial cell proliferation GO:0060252 9.91 TNF LTA IL6
14 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.88 TNF LTA
15 positive regulation of tumor necrosis factor production GO:0032760 9.85 SYK MIF IL6 IL1A IL17A
16 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.8 TNF LTA
17 response to amyloid-beta GO:1904645 9.8 MMP9 MMP3 MMP13
18 regulation of neuroinflammatory response GO:0150077 9.73 IL6 MMP3 MMP9
19 positive regulation of interleukin-6 production GO:0032755 9.65 TNF SYK IL6 IL1A IL17A
20 inflammatory response GO:0006954 9.53 TNFAIP6 TNF MIF MACIR IL6 IL1A

Molecular functions related to Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.44 TNF MIF LTA IL6 IL1A IL17A
Sources

Sources for Arthritis

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....